Group Leader

Dr Toby Tuthill

Group

Picornavirus Molecular Biology

Expertise

Molecular Biology, Structural biology, Virology

Dr Toby Tuthill

Group

Picornavirus Molecular Biology

Toby Tuthill is a virologist interested in the molecular mechanisms used by viruses in the picornavirus family. Current areas of interest include cell entry, replication, assembly, structure, antigenicity and evolution. Research is intended to improve our understanding of the biology of these viruses and to apply this knowledge towards improved control of disease.

Toby joined The Pirbright Institute as a Research Fellow in 2009 after ten years postdoctoral experience in the laboratory of Professor Dave Rowlands at the University of Leeds.

Publications

Folegatti P M, Ewer K J, Aley P K, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck E A, Dold C, Faust S N, Finn A, Flaxman A L, Hallis B, Heath P, Jenkin D, Lazarus R, Makinson R, Minassian A M, Pollock K M, Ramasamy M, Robinson H, Snape M, Tarrant R, Voysey M, Green C, Douglas A D, Hill A V S, Lambe T, Gilbert S C, Pollard A J, on behalf of Oxford COVID Vaccine Trial Group (2020)

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Journal The Lancet

Read abstract

Ward J C, Lasecka-Dykes L, Neil C, Adeyemi O, Gold S, McLean N, Wright C, Herod M R, Kealy D, Warner E, King D P, Tuthill T J, Rowlands D J, Stonehouse N J (2020)

The RNA pseudoknots in foot-and-mouth disease virus are dispensable for genome 1 replication but essential for the production of infectious virus.

Journal bioRxiv

Read abstract

Graham S P, McLean R K, Spencer A J, Belij-Rammerstorfer S, Wright D, Ulaszewska M, Edwards J C, Hayes J W P, Martini V, Thakur N, Conceicao C, Dietrich I, Shelton H, Waters R, Ludi A, Wilsden G, Browning C, Bialy D, Bhat S, Stevenson-Leggett P, Hollinghurst P, Gilbride C, Pulido D, Moffat K, Sharpe H, Allen E, Mioulet V, Chiu C, Newman J, Asfor A S, Burman A, Crossley S, Huo J, Owens R J, Carroll M, Hammond J A, Tchilian E, Bailey D, Charleston B, Gilbert S C, Tuthill T J, Lambe T (2020)

Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19

Journal npj Vaccines

Read abstract

Asfor A, Howe N, Grazioli S, Berryman S, Parekh K, Wilsden G, Ludi A, King D, Parida S, Brocchi E, Tuthill T (2020)

Detection of bovine antibodies against a conserved capsid epitope as the basis of a novel universal serological test for foot-and-mouth disease

Journal Journal of Clinical Microbiology

Read abstract

Shimmon G, Kotecha A, Ren J, Asfor A S, Newman J, Berryman S, Cottam E M, Gold S, Tuthill T J, King D P, Brocchi E, King A M Q, Owens R, Fry E E, Stuart D I, Burman A, Jackson T (2018)

Generation and characterisation of recombinant FMDV antibodies: Applications for advancing diagnostic and laboratory assays

Journal PLoS ONE

Read abstract

Pagination

Previous page
Page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
Next page

Articles

Two people with a giant red, green and blue FMDV model stood in front of a building

04 July 2024

Showcase for Pirbright-Diamond collaboration in virus imaging

Researchers from The Pirbright Institute, the University of Oxford’s Division of Structural Biology and Diamond Light Source have showcased their expertise at the Harwell Open Day, which highlights UK science and innovation to the public. Staged for the first time in eight years, the event gave the…

11 April 2022

Pirbright scientists investigate pig coronavirus infection to understand COVID-19 in humans

Researchers at Pirbright have developed a pig respiratory coronavirus (PRCV) model which will help to understand how coronaviruses cause disease and how the immune system responds to them. Human coronaviruses such as Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS…

22 January 2021

Early animal studies by Pirbright and Oxford yield promising results for new potential COVID-19 vaccine

Studies carried out by The Pirbright Institute and the University of Oxford have shown that Oxford’s new potential vaccine against COVID-19, named RBD-SpyVLP, produces a strong antibody response in mice and pigs, providing vital information for the further development of the vaccine. Although this…

23 June 2020

Studies at Pirbright demonstrate two doses of Oxford University’s COVID-19 vaccine boosts immune response in pigs

The Pirbright Institute, working in collaboration with the University of Oxford, have successfully shown that two doses of the ChAdOx1 nCoV-19 (AZD1222) vaccine produce a greater antibody response than a single dose in pigs. The emergence and subsequent spread of SARS-CoV-2 has caused a global…

22 April 2020

Pirbright develops universal foot-and-mouth disease virus test

A diagnostic test that can detect whether an animal has been infected by or vaccinated against any type of foot-and-mouth disease virus (FMDV) has been developed by scientists at The Pirbright Institute and Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna (IZSLER). The…

This scanning electron microscope image shows SARS-CoV-2 (yellow)—also known as 2019-nCoV, the virus that causes COVID-19—isolated from a patient in the U.S., emerging from the surface of cells (pink) cultured in the lab.

25 March 2020

Pirbright begins testing new coronavirus vaccines on animals to help combat COVID-19

The Pirbright Institute is joining in the global battle to help control COVID-19 by using its unique expertise and facilities to support the development of vaccines to protect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of the current pandemic. Working in…

bbsrc innovator of the year awards dr andrew broadbent and dr amin asfor

17 May 2019

Pirbright innovation recognised at the BBSRC Innovator of the Year Awards

Two scientists from The Pirbright Institute attended the BBSRC Innovator of the Year Awards on 15 May 2019 as shortlisted finalists. Dr Andrew Broadbent and Dr Amin Asfor pitched their research against ten other scientists and groups across four categories: Commercial Impact, Social Impact…

26 September 2018

Engineering ‘Fab’ new ways of reducing animal use in foot-and-mouth disease diagnostics

A novel foot-and-mouth disease (FMD) diagnostic reagent has been developed by scientists at The Pirbright Institute. This has the potential to be used in FMD diagnostic tests, and will be significantly quicker to produce when compared to existing test reagents due to a simplified production…

21 June 2018

Contact

Title

Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Dr Toby Tuthill

Publications

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

The RNA pseudoknots in foot-and-mouth disease virus are dispensable for genome 1 replication but essential for the production of infectious virus.

Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19

Detection of bovine antibodies against a conserved capsid epitope as the basis of a novel universal serological test for foot-and-mouth disease

Generation and characterisation of recombinant FMDV antibodies: Applications for advancing diagnostic and laboratory assays

Articles

Showcase for Pirbright-Diamond collaboration in virus imaging

Pirbright scientists investigate pig coronavirus infection to understand COVID-19 in humans

Early animal studies by Pirbright and Oxford yield promising results for new potential COVID-19 vaccine

Studies at Pirbright demonstrate two doses of Oxford University’s COVID-19 vaccine boosts immune response in pigs

Pirbright develops universal foot-and-mouth disease virus test

Pirbright begins testing new coronavirus vaccines on animals to help combat COVID-19

Pirbright innovation recognised at the BBSRC Innovator of the Year Awards

Engineering ‘Fab’ new ways of reducing animal use in foot-and-mouth disease diagnostics

Breakthrough could make the common cold not so common

Pirbright identifies two new genetic groups of foot-and-mouth disease virus

Foot-and-mouth disease protein could be used for disease detection

Protein shown vital for foot-and-mouth disease virus replication

New method of diagnosing foot-and-mouth disease will use fewer small animals

Contact